AVITA Medical Croissance future
Future contrôle des critères 5/6
AVITA Medical devrait augmenter ses bénéfices et son chiffre d'affaires de 65.1% et de 17.6% par an respectivement. Le BPA devrait croître de de 59.8% par an. Le rendement des capitaux propres devrait être 1019.6% dans 3 ans.
Informations clés
65.1%
Taux de croissance des bénéfices
59.75%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.1% |
| Taux de croissance des recettes | 17.6% |
| Rendement futur des capitaux propres | 1,019.60% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 02 Jul 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 29
RCEL: Execution And Cash Strength Will Drive Recovery And Multiple Expansion
Analysts have raised their price target on AVITA Medical to $6.00 from $3.50. They point to recent quarterly revenue performance, expectations for execution in line with or better than guidance, and an improved cash position as key reasons for a higher fair value estimate and a lower future P/E assumption in updated models.Mise à jour du récit • Jun 14
RCEL: Execution And Cash Strength Are Expected To Drive Future Upside
Narrative update The analyst price target for AVITA Medical has risen by $2.50 to $6.00, with analysts highlighting the recent stock pullback, the latest Q1 revenue level, and expectations for execution and cash position as key supports for this revision. Analyst Commentary Bullish analysts are pointing to the recent price target reset and rating change as a sign of renewed confidence in AVITA Medical after the latest quarterly update.Mise à jour du récit • May 31
RCEL: Market Recovery And Cash Progress Are Expected To Drive Upside
Analysts have slightly adjusted the AVITA Medical price target to reflect updated assumptions for growth, margins and future P/E. They continue to reference Street research that highlights improving execution, Lake Street’s higher $6 target, and Northland's $10 target supported by expectations for revenue recovery, cash progress and a large addressable market.
Mise à jour du récit • May 10
RCEL: Low Market Penetration And FY27 Cash Breakeven Will Drive Repricing
Analysts have trimmed their price target for AVITA Medical to $5.49 from $5.52, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E after recent research highlighted low current market penetration, a roughly $1.3b total addressable market, reimbursement stabilization, and an outlook for potential cash breakeven during FY27. Analyst Commentary Recent research points to a mixed backdrop for AVITA Medical, with analysts updating their models around a roughly $1.3b total addressable market, low current market penetration of about 5%, and expectations tied to reimbursement trends and the path toward a potential cash breakeven during FY27.Mise à jour du récit • Apr 25
RCEL: Market Penetration And Burn Preparedness Agreement Will Support Constructive Upside
Narrative Update on AVITA Medical The Analyst Price Target for AVITA Medical has been adjusted from $10.02 to about $10.16. Analysts point to updated views on revenue growth and profit margins, as well as recent Northland research highlighting market penetration, product differentiation, reimbursement trends and the path toward cash breakeven as key supports for this change.Mise à jour du récit • Apr 11
RCEL: Reimbursement Stability And FY27 Cash Breakeven Frame Balanced Risk Reward Outlook
The analyst price target for AVITA Medical has been revised slightly higher to reflect an updated fair value of about $5.52, up from roughly $5.33. Analysts point to expectations for revenue growth, stable profit margins, and recent research citing product differentiation, reimbursement stabilization, and progress toward cash breakeven as key drivers of their refreshed view.Mise à jour du récit • Mar 28
RCEL: Reimbursement Stability And FY27 Cash Breakeven Drive Bullish Rerating Potential
Analysts have trimmed their blended valuation for AVITA Medical, with the updated fair value estimate easing from about $5.44 to $5.33 per share. This reflects revised assumptions on revenue growth, profit margins, and a lower future P/E multiple informed by recent research that highlights both the pullback in the stock and expectations for double digit top line expansion over time.Mise à jour du récit • Mar 13
RCEL: Reimbursement Stability And Cash Breakeven Path Will Underpin Renewed Market Confidence
Analysts have lifted their AVITA Medical price target to $10, supported by expectations for renewed double digit revenue growth from a roughly $1.3b addressable market, reimbursement stabilization, and a path to potential cash breakeven around FY27. Analyst Commentary Recent coverage has highlighted a mixed but generally constructive view on AVITA Medical, with the latest initiation pointing to a $10 price target.Mise à jour du récit • Feb 27
RCEL: Refined Earnings Assumptions And Burn Data Will Support Constructive Upside
Analysts have nudged their average price target on AVITA Medical up by $0.50 per share, citing updated assumptions around revenue growth, profit margins and P/E multiples that modestly refine their valuation models. Analyst Commentary Recent bullish analysts have framed the $0.50 uplift in the average price target as a refinement rather than a wholesale reset.Mise à jour du récit • Feb 13
RCEL: Ongoing Burn And Wound Data Will Support Constructive Long-Term Upside
Analysts have adjusted their price target on AVITA Medical to $10.07 from $14.10, reflecting updated views on fair value, discount rate, revenue growth and profit margin assumptions that are broadly consistent with recent Street research, including the modest target raise cited by Lake Street. Analyst Commentary Recent price target work on AVITA Medical points to a more constructive tone among bullish analysts, even if some models still embed conservative assumptions on execution and profitability.Mise à jour du récit • Jan 30
RCEL: Elevated Expectations For 2026 Guidance Will Expose Fragile Market Confidence
Narrative Update: AVITA Medical Analysts have raised their price target on AVITA Medical to about US$3.61 from roughly US$3.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E as key factors behind the revised assessment. Analyst Commentary Even with a higher price target around US$3.61, bearish analysts remain cautious and describe the move as a fine tuning of assumptions rather than a strong endorsement of upside potential.Article d’analyse • Jan 24
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...
Mise à jour du récit • Jan 16
RCEL: Two Year Revenue Guidance Reset Will Support Bullish Repricing
Analysts have adjusted their price target for AVITA Medical, reflecting a lower implied fair value of $6.98, down from $7.32. They cite updated assumptions around revenue growth, profit margins, and a reduced future P/E multiple.Article d’analyse • Nov 09
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
AVITA Medical, Inc. ( NASDAQ:RCEL ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Mise à jour du récit • Nov 08
RCEL: Leadership Transition And Guidance Reset Will Drive Second Half Recovery
Analysts have lowered their price target for AVITA Medical from $8.00 to $4.00. They cite weaker-than-expected Q3 revenue, leadership changes, and the need to amend debt agreements as key factors in their revised outlook.Article d’analyse • Oct 03
AVITA Medical, Inc. (NASDAQ:RCEL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Mise à jour du récit • Sep 17
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Analysts have markedly reduced AVITA Medical’s price target from $9.60 to $8.26 amid lowered guidance, recurring earnings misses, and ongoing reimbursement headwinds that are pressuring demand and raising solvency concerns despite management’s optimism for a second-half recovery. Analyst Commentary Materially lowered guidance has prompted a significant reset of expectations, but management maintains confidence in a second half recovery.Mise à jour du récit • Aug 15
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
AVITA Medical’s consensus price target remains unchanged as analysts respond to materially reduced guidance and persistent reimbursement issues—with bulls viewing the lowered expectations as prudent and bears citing execution risks and near-term revenue headwinds—leaving the fair value steady at $9.60. Analyst Commentary Materially reduced guidance led to significant downward revisions in price targets.Article d’analyse • Aug 10
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25%
Unfortunately for some shareholders, the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has dived 25% in the last...Article d’analyse • May 29
Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation
Key Insights AVITA Medical will host its Annual General Meeting on 4th of June CEO Jim Corbett's total compensation...
Nouveau récit • Apr 24
PermeaDerm And Cohealyx Will Open International Markets
Launching new products and expanding internationally are expected to drive significant revenue growth and market penetration.Article d’analyse • Mar 06
Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel
AVITA Medical, Inc.'s ( NASDAQ:RCEL ) price-to-sales (or "P/S") ratio of 3.5x might make it look like a strong buy...Article d’analyse • Dec 30
Is AVITA Medical (NASDAQ:RCEL) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Dec 03
AVITA Medical, Inc.'s (NASDAQ:RCEL) Shares Bounce 26% But Its Business Still Trails The Industry
AVITA Medical, Inc. ( NASDAQ:RCEL ) shares have continued their recent momentum with a 26% gain in the last month...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 126 | 2 | 4 | 11 | 7 |
| 12/31/2027 | 105 | -13 | -9 | -1 | 8 |
| 12/31/2026 | 81 | -34 | -29 | -28 | 8 |
| 3/31/2026 | 72 | -45 | -32 | -31 | N/A |
| 12/31/2025 | 72 | -49 | -33 | -31 | N/A |
| 9/30/2025 | 72 | -49 | -37 | -34 | N/A |
| 6/30/2025 | 75 | -52 | -42 | -36 | N/A |
| 3/31/2025 | 72 | -57 | -47 | -38 | N/A |
| 12/31/2024 | 64 | -62 | -58 | -49 | N/A |
| 9/30/2024 | 60 | -57 | -60 | -52 | N/A |
| 6/30/2024 | 54 | -50 | -58 | -53 | N/A |
| 3/31/2024 | 51 | -45 | -52 | -50 | N/A |
| 12/31/2023 | 50 | -35 | -39 | -38 | N/A |
| 9/30/2023 | 45 | -34 | -32 | -31 | N/A |
| 6/30/2023 | 41 | -31 | -25 | -24 | N/A |
| 3/31/2023 | 37 | -26 | -20 | -19 | N/A |
| 12/31/2022 | 34 | -27 | -20 | -19 | N/A |
| 9/30/2022 | 32 | -30 | -21 | -21 | N/A |
| 6/30/2022 | 30 | -30 | -19 | -18 | N/A |
| 3/31/2022 | 32 | -29 | -19 | -19 | N/A |
| 12/31/2021 | 33 | -25 | -19 | -18 | N/A |
| 9/30/2021 | 31 | -22 | -20 | -19 | N/A |
| 6/30/2021 | 29 | -27 | -27 | -26 | N/A |
| 3/31/2021 | 23 | -35 | -29 | -28 | N/A |
| 12/31/2020 | 18 | -44 | -28 | -27 | N/A |
| 9/30/2020 | 16 | -49 | -27 | -26 | N/A |
| 6/30/2020 | 14 | -42 | -24 | -23 | N/A |
| 3/31/2020 | 12 | -36 | -24 | -23 | N/A |
| 12/31/2019 | 11 | -28 | N/A | -21 | N/A |
| 9/30/2019 | 8 | -23 | N/A | -21 | N/A |
| 6/30/2019 | 5 | -25 | N/A | -19 | N/A |
| 3/31/2019 | 4 | -22 | N/A | -18 | N/A |
| 12/31/2018 | 2 | -18 | N/A | -13 | N/A |
| 9/30/2018 | 1 | -15 | N/A | -13 | N/A |
| 6/30/2018 | 1 | -13 | N/A | -13 | N/A |
| 3/31/2018 | 1 | -12 | N/A | -11 | N/A |
| 12/31/2017 | 1 | -11 | N/A | -9 | N/A |
| 9/30/2017 | 1 | -10 | N/A | -8 | N/A |
| 6/30/2017 | 1 | -9 | N/A | -7 | N/A |
| 3/31/2017 | 1 | -8 | N/A | -6 | N/A |
| 12/31/2016 | 1 | -7 | N/A | -6 | N/A |
| 9/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 6/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 3/31/2016 | 1 | -8 | N/A | -7 | N/A |
| 12/31/2015 | 1 | -7 | N/A | -7 | N/A |
| 9/30/2015 | 1 | -6 | N/A | -5 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: RCEL devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3.5% ).
Bénéfices vs marché: RCEL devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: RCEL devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de RCEL ( 17.6% par an) devrait croître plus rapidement que le marché US ( 12.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de RCEL ( 17.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de RCEL devrait être très élevé dans 3 ans ( 1019.6 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/09 14:59 |
| Cours de l'action en fin de journée | 2026/07/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
AVITA Medical, Inc. est couverte par 13 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Laura McGuigan | B. Riley Securities, Inc. |